Vanguard Group Inc Liquidia Corp Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LQDA
# of Institutions
157Shares Held
35.5MCall Options Held
1.68MPut Options Held
1.17M-
Patient Square Capital LP Menlo Park, CA7.18MShares$85.9 Million45.11% of portfolio
-
Black Rock Inc. New York, NY3.75MShares$44.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ2.25MShares$26.9 Million3.48% of portfolio
-
Findell Capital Management LLC New York, NY2.11MShares$25.2 Million16.28% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.06MShares$24.6 Million0.14% of portfolio
About Liquidia Corp
- Ticker LQDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,362,300
- Market Cap $770M
- Description
- Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...